← All deals

BRIDGE TO LIFE LTD

Other Health CareB2BOrgan PreservationPerfusion Technology
πŸ“ Duluth, GA, United Statesβ€’ Founded 2005
StreetZero Signal 73
Be the first to signal interest

About BRIDGE TO LIFE LTD

Bridge to Life Ltd. is a privately held B2B company founded in 2005 that develops organ preservation solutions and perfusion technologies for transplantation. Its flagship product is the VitaSmartβ„’ hypothermic oxygenated perfusion (HOPE) system, which it acquired from Medica S.p.A. The company focuses on commercial development of preservation technologies and organ infusion systems, with operations supporting transplant specialists globally. It maintains a customer focus on product sales in the healthcare sector.

LATEST FUNDINGPrivate Placement
$82.5M
Announced 2026-10-21
TOTAL RAISED$167M
πŸ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for BRIDGE TO LIFE LTD.

Free plan includes 3 full deal profiles every month.

Key highlights

  • Raised $110 million in Series C and debt financing in August 2026 led by Soleus Capital to expand VitaSmart commercialization.
  • Earlier $56 million round in 2024 led by Perceptive Advisors supported preservation technologies and organ infusion systems.
  • Acquired VitaSmart system from Medica S.p.A. and achieved UK NICE guidance recommending NHS funding.
  • Total funding reaches $167 million over five rounds with four institutional investors participating.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account